NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Ah; the much-referred to 23-patient Phase 2 study, which was used to demonstrate the use and possible additional survival benefit of either of the two adjuvants.
The same study was also used to demonstrate the non stat-sig additional benefit accrued by mesenchymal patients.

I'm pretty sure this is all one and the same study (though if anyone can demonstrate otherwise, I'd be happy to accept..)

8 of the 23 were rGBM rather than ndGBM.

So you have lots of variables and very small numbers, so there really isn't much in the way of statistical significance that can be attached to the outcomes (though your quote did claim one stat sig outcome). Additionally, some got post-vacc TMZ, some didn't, some got Bev and others didn't.

That's why personally I don't conclude that use of an adjuvant necessarily confers additional survival advantage (nor do I discount the possibility), and similarly, I don't conclude that L definitely works better with mesenchymal, though again, I don't discount it either.

Full study report is here:-

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071163/

(Table 1 gives patient characteristics of each and every one of the 23, whether or not they got one of the adjuvants, which gene expression profile they were, and what additional treatments they received. So you can dive into the individual outcomes of each patient and draw the conclusions that you think are valid and worth making.)